Shares of Antares Pharma, Inc. (NASDAQ:ATRS) have received an average rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $3.94.

A number of equities research analysts recently commented on ATRS shares. Raymond James Financial, Inc. started coverage on Antares Pharma in a report on Thursday, April 20th. They issued a “strong-buy” rating and a $4.30 price objective for the company. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Antares Pharma in a report on Friday, June 23rd. Chardan Capital began coverage on Antares Pharma in a report on Friday, June 23rd. They issued a “buy” rating and a $5.00 price target for the company. Finally, Vetr downgraded Antares Pharma from a “strong-buy” rating to a “buy” rating and set a $3.47 price target for the company. in a report on Monday, June 26th.

In other Antares Pharma news, insider Fred M. Powell purchased 130,000 shares of the stock in a transaction on Friday, June 9th. The stock was bought at an average cost of $2.79 per share, for a total transaction of $362,700.00. Following the completion of the acquisition, the insider now directly owns 331,434 shares of the company’s stock, valued at $924,700.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 11.60% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the company. KCG Holdings Inc. boosted its position in Antares Pharma by 48.8% in the first quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 21,881 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Antares Pharma by 10.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 289,093 shares of the specialty pharmaceutical company’s stock valued at $822,000 after buying an additional 26,847 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Antares Pharma by 20.1% in the first quarter. Bank of New York Mellon Corp now owns 167,515 shares of the specialty pharmaceutical company’s stock valued at $476,000 after buying an additional 28,029 shares in the last quarter. Thompson Davis & CO. Inc. boosted its position in Antares Pharma by 80.8% in the first quarter. Thompson Davis & CO. Inc. now owns 68,386 shares of the specialty pharmaceutical company’s stock valued at $194,000 after buying an additional 30,560 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Antares Pharma by 4.8% in the first quarter. Geode Capital Management LLC now owns 958,234 shares of the specialty pharmaceutical company’s stock valued at $2,721,000 after buying an additional 43,629 shares in the last quarter. Institutional investors own 32.04% of the company’s stock.

WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/07/21/antares-pharma-inc-atrs-given-average-recommendation-of-buy-by-brokerages.html.

Antares Pharma (NASDAQ ATRS) traded down 1.92% during trading on Friday, hitting $3.07. The company had a trading volume of 321,034 shares. The firm has a 50-day moving average of $3.02 and a 200 day moving average of $2.68. Antares Pharma has a 12-month low of $0.98 and a 12-month high of $3.37. The company’s market capitalization is $478.69 million.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. The business had revenue of $12.01 million during the quarter, compared to the consensus estimate of $12.10 million. Antares Pharma had a negative return on equity of 45.05% and a negative net margin of 41.26%. On average, equities research analysts forecast that Antares Pharma will post ($0.13) earnings per share for the current year.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.